Skip to product information
1 of 1

GeneBio Systems

Recombinant Mouse TNFRSF17/BCMA Protein (His & Fc Tag)

Recombinant Mouse TNFRSF17/BCMA Protein (His & Fc Tag)

SKU:PKSM040938

Regular price $1,048.00 USD
Regular price Sale price $1,048.00 USD
Sale Sold out
Shipping calculated at checkout.

Size: 100μg

Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

Shipping: This product is provided as lyophilized powder which is shipped with ice packs.

Exp date: 12 months

Category ID_II: Recombinant Proteins

Category ID_III: Others

Abbreviation:

Target Synonym: B-cell maturation protein;BCM;BCMA;CD269;Tnfrsf13;Tnfrsf13a;Tnfrsf17;Tumor necrosis factor receptor superfamily member 17

Research Areas:

Conjugation:

Target Species: Mouse

Expression Host: HEK293 Cells

Application: ELISA

Fusion tag: C-His-Fc

UNIProt ID: O88472

Accession: NP_035738.1

Background: Tumor necrosis factor receptor superfamily, member 17 (TNFRSF17), also known as B cell maturation antigen (BCMA) or CD269 antigen, is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13BBAFF), and to lead to NF-kappaB and MAPK8/JNK activation. TNFRSF17/BCMA/CD269 also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. TNFRSF17/BCMA/CD269 is a receptor for TALL-1 and BCMA activates NF-kappaB through a TRAF5-, TRAF6-, NIK-, and IKK-dependent pathway. The identification of TNFRSF17 as a NF-kappaB-activating receptor for TALL-1 suggests molecular targets for drug development against certain immunodeficient or autoimmune diseases. TNFRSF17/BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo.

Concentration:

Activity: Immobilized human BAFF at 10 μg/ml (100 μl/well) can bind mouse BCMA-Fch, The EC50 of mouse BCMA-Fch is 0.02-0.06 μg/mL.

Sequence: Met 1-Thr 49

Purity: > 90 % as determined by reducing SDS-PAGE.

Formulation: Lyophilized from sterile PBS, pH 7.4
Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.

Reconstitution: Please refer to the printed manual for detailed information.

Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.

Calculated MW: 33.7 kDa

ObservedMW: 35-48 kDa

View full details